Correlation Between Alnylam Pharmaceuticals and Vertex Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Alnylam Pharmaceuticals and Vertex Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Alnylam Pharmaceuticals and Vertex Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Alnylam Pharmaceuticals and Vertex Pharmaceuticals, you can compare the effects of market volatilities on Alnylam Pharmaceuticals and Vertex Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Alnylam Pharmaceuticals with a short position of Vertex Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Alnylam Pharmaceuticals and Vertex Pharmaceuticals.

Diversification Opportunities for Alnylam Pharmaceuticals and Vertex Pharmaceuticals

0.41

Correlation Coefficient

Alnylam Pharmaceuticals  Vertex Pharmaceuticals

Very weak diversification

The 3 months correlation between Alnylam and Vertex is 0.41. Overlapping area represents the amount of risk that can be diversified away by holding Alnylam Pharmaceuticals and Vertex Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Vertex Pharmaceuticals and Alnylam Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Alnylam Pharmaceuticals are associated (or correlated) with Vertex Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Vertex Pharmaceuticals has no effect on the direction of Alnylam Pharmaceuticals i.e., Alnylam Pharmaceuticals and Vertex Pharmaceuticals go up and down completely randomly.

Pair Corralation between Alnylam Pharmaceuticals and Vertex Pharmaceuticals

Given the investment horizon of 90 days Alnylam Pharmaceuticals is expected to generate 1.29 times more return on investment than Vertex Pharmaceuticals. However, Alnylam Pharmaceuticals is 1.29 times more volatile than Vertex Pharmaceuticals. It trades about 0.01 of its potential returns per unit of risk. Vertex Pharmaceuticals is currently generating about -0.01 per unit of risk. If you would invest  25,378  in Alnylam Pharmaceuticals on September 3, 2024 and sell it today you would lose (71.00) from holding Alnylam Pharmaceuticals or give up 0.28% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Alnylam Pharmaceuticals  vs.  Vertex Pharmaceuticals

Alnylam Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Alnylam Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Alnylam Pharmaceuticals is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.

Vertex Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Vertex Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Vertex Pharmaceuticals is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Alnylam Pharmaceuticals and Vertex Pharmaceuticals

The main advantage of trading using opposite Alnylam Pharmaceuticals and Vertex Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Alnylam Pharmaceuticals position performs unexpectedly, Vertex Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vertex Pharmaceuticals will offset losses from the drop in Vertex Pharmaceuticals' long position.

The idea behind Alnylam Pharmaceuticals and Vertex Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.